AUS
NZ
UK
CA
USA
IND
Fisher & Paykel Healthcare Corporation Limited (ASX:FPH) has submitted an application to list 13,781 newly issued ordinary shares on the ASX, allocated to North American employees through the company’s Employee Stock Purchase Plan. These shares were issued on 1 July 2026 at NZD $33.1882 each, increasing the total quoted securities of the company. This update underscores Fisher & Paykel Healthcare’s ongoing commitment to its long-term employee incentive programs, which align employee interests with those of shareholders across its global workforce.<\/p> <\/div>
Key Points<\/h3>
- Company: Fisher & Paykel Healthcare Corporation Limited (ASX:FPH)<\/li>
- Application made for quotation of 13,781 new fully paid ordinary shares on ASX, issued under the Employee Stock Purchase Plan<\/li>
- Shares issued on 1 July 2026 at NZD $33.1882 per share to North American employees<\/li>
- Key Management Personnel Justin Callahan received 142 shares under the plan<\/li>
- Total quoted ordinary shares on ASX now total 587,302,790 following this issuance<\/li>
- Investors should monitor future employee incentive issuances and any changes to FPH’s remuneration framework<\/li>
<\/ul>
<\/div>
Fisher & Paykel Healthcare Issues Shares to North American Employees Through ESPP in July 2026<\/h2>
Fisher & Paykel Healthcare Corporation Limited has applied to the ASX for the quotation of 13,781 new ordinary fully paid shares issued to employees participating in its Employee Stock Purchase Plan (ESPP). The shares were issued on 1 July 2026, with the quotation application submitted on 2 July 2026. The shares were offered to North American employees who accepted the invitation to participate.<\/p>
The ESPP is part of several long-term variable remuneration programs run by Fisher & Paykel Healthcare. Full details of the plan are publicly accessible on the company’s corporate governance webpage, outlining its approach to long-term variable remuneration. This issuance represents a routine but significant method by which the company distributes equity to its workforce in a key geographic region.<\/p>
Issue Price of NZD $33.1882 Reflects Company Valuation at Time of Share Allocation<\/h2>
The 13,781 shares were issued at NZD $33.1882 per share, denominated in New Zealand dollars. As a New Zealand-incorporated company with a foreign exempt ASX listing, Fisher & Paykel Healthcare’s primary listing is on the NZX, with the ASX serving as a secondary market for Australian investors. The issue price reflects the valuation applied under the ESPP at the time of allocation.<\/p>
Since these shares are issued under an employee incentive plan rather than a capital raising open to the public, the price is determined by the plan’s rules rather than a market bookbuild or placement. The company did not specify in this update the exact pricing methodology or whether the price includes a discount to market price, which is common in employee stock purchase plans elsewhere. Investors seeking details on pricing methodology should consult the plan terms on Fisher & Paykel Healthcare’s website.<\/p>
KMP Justin Callahan Allocated 142 Shares Under the ESPP<\/h2>
The update reveals that Key Management Personnel Justin Callahan received 142 shares under the ESPP, registered in his name. Disclosure of KMP participation complies with ASX Listing Rules to ensure transparency of equity holdings by senior executives influencing company decisions.<\/p>
The 142 shares represent a small fraction of the total 13,781 shares issued in this tranche. The company did not disclose Mr Callahan’s specific role or title in this update. Interested investors can refer to the company’s Annual Report or other disclosures for details on his responsibilities. The inclusion of KMP in the ESPP highlights the plan’s broad-based nature, encompassing both senior management and general employees.<\/p>
Total ASX Quoted Shares Reach 587,302,790 Following New Issuance<\/h2>
After the addition of 13,781 new ordinary shares, Fisher & Paykel Healthcare’s total quoted shares on the ASX stand at 587,302,790 fully paid foreign exempt NZX shares. This figure is based on the company’s current share registry but may not fully reflect issued capital if other transactions are concurrently processed by the ASX.<\/p>
The increase of approximately 0.002% in total share capital is negligible in terms of dilution. Nonetheless, it forms part of a broader pattern of equity issuances under the company’s employee incentive schemes, contributing to gradual share count growth over time.<\/p>
Substantial Unquoted Securities Indicate Mature Long-Term Incentive Programs<\/h2>
Beyond the newly quoted shares, the company holds a significant volume of unquoted securities across multiple incentive tranches, including employee share rights, performance share rights, and options with various expiry dates and exercise prices. Notable classes include options expiring in January 2028 at NZD $37.39 (689,420 securities), options expiring in January 2029 at NZD $36.73 (10,997 securities), and multiple performance share rights expiring between 2025 and 2028.<\/p>
The diversity of these unquoted instruments across at least 13 classes demonstrates the complexity and maturity of Fisher & Paykel Healthcare’s long-term remuneration approach. As these instruments vest or are exercised, further applications for quotation similar to this one are expected. Investors should consider the potential dilution from these unquoted securities, which number in the hundreds of thousands.<\/p>
Foreign Exempt NZX Listing Influences Governance and Trading of FPH Shares on ASX<\/h2>
Fisher & Paykel Healthcare’s foreign exempt listing on the ASX means its primary regulatory compliance is under NZX rules rather than the full ASX Listing Rules applicable to domestic Australian companies. This structure is typical for New Zealand companies accessing Australian capital markets without duplicating regulatory requirements.<\/p>
Australian investors should note that some ASX disclosure and governance requirements differ for foreign exempt listings. However, material events like the quotation of new shares are still reported via the ASX, ensuring market participants have access to relevant information. The shares are classified as "ordinary fully paid foreign exempt NZX" securities, confirming their dual-market status and NZX regulatory primacy.<\/p>
Employee Stock Purchase Plan Supports Retention in Key International Markets<\/h2>
Employee share purchase plans are common tools for multinational companies to attract and retain talent in competitive sectors such as healthcare technology, Fisher & Paykel Healthcare’s core area. By enabling employees to acquire shares, often at a discount or through structured savings, companies align employee incentives with long-term shareholder value creation.<\/p>
This tranche’s focus on North American employees is significant given the strategic importance of that market for the company’s respiratory and acute care products. The company did not disclose the number of participating employees or total value of shares acquired in this round. Investors seeking this information may consult the company’s annual remuneration report or investor presentations. The plan’s terms are summarized on the company’s website under long-term variable remuneration disclosures.<\/p>
New Shares Rank Equally With Existing Ordinary Shares From Issue Date<\/h2>
The company confirmed that the 13,781 newly issued shares rank equally with existing ordinary shares from their issue date of 1 July 2026. They carry identical dividend rights, voting rights, and other shareholder entitlements. No transfer restrictions were disclosed, and the shares are being applied for quotation as freely tradable securities on the ASX.<\/p>
This equal ranking is standard for employee incentive shares and ensures fairness within the company’s capital structure. Existing shareholders are assured that these shares hold no preferential rights. The issuance does not require additional shareholder approval beyond what was obtained when the ESPP was established.<\/p>
Investor Considerations Following the ESPP Share Quotation<\/h2>
Investors monitoring Fisher & Paykel Healthcare’s equity should watch for upcoming vesting and conversion of unquoted performance share rights, employee share rights, and options. Several instruments have near-term expiry or vesting dates, including performance share rights expiring October 2025 and options expiring January 2026, which may lead to further quotation applications soon.<\/p>
Additionally, investors may focus on the company’s forthcoming financial results, updates on its respiratory humidification and hospital care product pipeline, and management commentary on trading conditions across key regions including North America, Europe, and Asia-Pacific. The immediate share price impact of this 13,781-share issuance is likely minimal due to its small scale. However, the ongoing ESPP operation reflects management’s confidence in the company’s long-term equity value as employees voluntarily acquire shares at market-referenced prices.<\/p>
Fisher & Paykel Healthcare Issues Shares to North American Employees Through ESPP in July 2026<\/h2>
Fisher & Paykel Healthcare Corporation Limited has applied to the ASX for the quotation of 13,781 new ordinary fully paid shares issued to employees participating in its Employee Stock Purchase Plan (ESPP). The shares were issued on 1 July 2026, with the quotation application submitted on 2 July 2026. The shares were offered to North American employees who accepted the invitation to participate.<\/p>
The ESPP is part of several long-term variable remuneration programs run by Fisher & Paykel Healthcare. Full details of the plan are publicly accessible on the company’s corporate governance webpage, outlining its approach to long-term variable remuneration. This issuance represents a routine but significant method by which the company distributes equity to its workforce in a key geographic region.<\/p>
Issue Price of NZD $33.1882 Reflects Company Valuation at Time of Share Allocation<\/h2>
The 13,781 shares were issued at NZD $33.1882 per share, denominated in New Zealand dollars. As a New Zealand-incorporated company with a foreign exempt ASX listing, Fisher & Paykel Healthcare’s primary listing is on the NZX, with the ASX serving as a secondary market for Australian investors. The issue price reflects the valuation applied under the ESPP at the time of allocation.<\/p>
Since these shares are issued under an employee incentive plan rather than a capital raising open to the public, the price is determined by the plan’s rules rather than a market bookbuild or placement. The company did not specify in this update the exact pricing methodology or whether the price includes a discount to market price, which is common in employee stock purchase plans elsewhere. Investors seeking details on pricing methodology should consult the plan terms on Fisher & Paykel Healthcare’s website.<\/p>
KMP Justin Callahan Allocated 142 Shares Under the ESPP<\/h2>
The update reveals that Key Management Personnel Justin Callahan received 142 shares under the ESPP, registered in his name. Disclosure of KMP participation complies with ASX Listing Rules to ensure transparency of equity holdings by senior executives influencing company decisions.<\/p>
The 142 shares represent a small fraction of the total 13,781 shares issued in this tranche. The company did not disclose Mr Callahan’s specific role or title in this update. Interested investors can refer to the company’s Annual Report or other disclosures for details on his responsibilities. The inclusion of KMP in the ESPP highlights the plan’s broad-based nature, encompassing both senior management and general employees.<\/p>
Total ASX Quoted Shares Reach 587,302,790 Following New Issuance<\/h2>
After the addition of 13,781 new ordinary shares, Fisher & Paykel Healthcare’s total quoted shares on the ASX stand at 587,302,790 fully paid foreign exempt NZX shares. This figure is based on the company’s current share registry but may not fully reflect issued capital if other transactions are concurrently processed by the ASX.<\/p>
The increase of approximately 0.002% in total share capital is negligible in terms of dilution. Nonetheless, it forms part of a broader pattern of equity issuances under the company’s employee incentive schemes, contributing to gradual share count growth over time.<\/p>
Substantial Unquoted Securities Indicate Mature Long-Term Incentive Programs<\/h2>
Beyond the newly quoted shares, the company holds a significant volume of unquoted securities across multiple incentive tranches, including employee share rights, performance share rights, and options with various expiry dates and exercise prices. Notable classes include options expiring in January 2028 at NZD $37.39 (689,420 securities), options expiring in January 2029 at NZD $36.73 (10,997 securities), and multiple performance share rights expiring between 2025 and 2028.<\/p>
The diversity of these unquoted instruments across at least 13 classes demonstrates the complexity and maturity of Fisher & Paykel Healthcare’s long-term remuneration approach. As these instruments vest or are exercised, further applications for quotation similar to this one are expected. Investors should consider the potential dilution from these unquoted securities, which number in the hundreds of thousands.<\/p>
Foreign Exempt NZX Listing Influences Governance and Trading of FPH Shares on ASX<\/h2>
Fisher & Paykel Healthcare’s foreign exempt listing on the ASX means its primary regulatory compliance is under NZX rules rather than the full ASX Listing Rules applicable to domestic Australian companies. This structure is typical for New Zealand companies accessing Australian capital markets without duplicating regulatory requirements.<\/p>
Australian investors should note that some ASX disclosure and governance requirements differ for foreign exempt listings. However, material events like the quotation of new shares are still reported via the ASX, ensuring market participants have access to relevant information. The shares are classified as "ordinary fully paid foreign exempt NZX" securities, confirming their dual-market status and NZX regulatory primacy.<\/p>
Employee Stock Purchase Plan Supports Retention in Key International Markets<\/h2>
Employee share purchase plans are common tools for multinational companies to attract and retain talent in competitive sectors such as healthcare technology, Fisher & Paykel Healthcare’s core area. By enabling employees to acquire shares, often at a discount or through structured savings, companies align employee incentives with long-term shareholder value creation.<\/p>
This tranche’s focus on North American employees is significant given the strategic importance of that market for the company’s respiratory and acute care products. The company did not disclose the number of participating employees or total value of shares acquired in this round. Investors seeking this information may consult the company’s annual remuneration report or investor presentations. The plan’s terms are summarized on the company’s website under long-term variable remuneration disclosures.<\/p>
New Shares Rank Equally With Existing Ordinary Shares From Issue Date<\/h2>
The company confirmed that the 13,781 newly issued shares rank equally with existing ordinary shares from their issue date of 1 July 2026. They carry identical dividend rights, voting rights, and other shareholder entitlements. No transfer restrictions were disclosed, and the shares are being applied for quotation as freely tradable securities on the ASX.<\/p>
This equal ranking is standard for employee incentive shares and ensures fairness within the company’s capital structure. Existing shareholders are assured that these shares hold no preferential rights. The issuance does not require additional shareholder approval beyond what was obtained when the ESPP was established.<\/p>
Investor Considerations Following the ESPP Share Quotation<\/h2>
Investors monitoring Fisher & Paykel Healthcare’s equity should watch for upcoming vesting and conversion of unquoted performance share rights, employee share rights, and options. Several instruments have near-term expiry or vesting dates, including performance share rights expiring October 2025 and options expiring January 2026, which may lead to further quotation applications soon.<\/p>
Additionally, investors may focus on the company’s forthcoming financial results, updates on its respiratory humidification and hospital care product pipeline, and management commentary on trading conditions across key regions including North America, Europe, and Asia-Pacific. The immediate share price impact of this 13,781-share issuance is likely minimal due to its small scale. However, the ongoing ESPP operation reflects management’s confidence in the company’s long-term equity value as employees voluntarily acquire shares at market-referenced prices.<\/p>
